Physician profile
Doris A Hamawy
NPI 1003966128
$5,102.72
in general payments reported to CMS, 2019-2025
30 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $79.75 · 2021: $349 · 2022: $403 · 2023: $799 · 2024: $1,086 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $996.11 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $966.46 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $451.57 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $345.99 | 2019-2025 | |
| Madrigal Pharmaceuticals | $283.11 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $225.78 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $205.31 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $201.07 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $183.63 | 2019-2023 | Xarelto |
| Heartflow, INC. | $146.70 | 2025 | |
| Gilead Sciences, INC. | $140.48 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $124.94 | 2024 | Voquezna |
| Astellas Pharma US INC | $121.82 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $96.13 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $85.08 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.04 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $63.96 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.65 | 2019 | |
| Abbott Laboratories | $48.97 | 2023-2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $48.31 | 2023 | Quviviq |
| Amarin Pharma, INC. | $33.15 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $31.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $30.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.96 | 2022 | |
| Eisai INC. | $24.58 | 2025 | |
| Phadia US INC. | $23.13 | 2023 | Immunocap |
| Endo Pharmaceuticals INC. | $20.00 | 2019 | |
| Lucid Diagnostics INC. | $18.10 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.76 | 2025 | Recorlev |
| Merck Sharp & Dohme LLC | $16.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Hamawy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.